Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy

­­­Comprehensive transcriptomic profiling identifies breast cancer patients who may be spared adjuvant systemic therapy

(2019) Martin Sjöström et al.   CLINICAL CANCER RESEARCH

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial

(2019) J M S Bartlett et al.   ANNALS OF ONCOLOGY

Lymph/angiogenesis contributes to sex differences in lung cancer through oestrogen receptor alpha signalling

(2018) Charline Dubois et al.   ENDOCRINE-RELATED CANCER

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

(2017) Laura J. Esserman et al.   JAMA Oncology

Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial

(2016) Maria Ekholm et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer

(2013) Edward B. Garon et al.   Journal of Thoracic Oncology

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

(2011) P-L Jerevall et al.   BRITISH JOURNAL OF CANCER

Lung cancer mortality risk among breast cancer patients treated with anti-estrogens

(2011) Christine Bouchardy et al.   CANCER

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

(2010) Jack Cuzick et al.   LANCET ONCOLOGY

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Menopausal hormone therapy and risk of lung cancer—Systematic review and meta-analysis

(2009) Claudia M. Greiser et al.   MATURITAS